Clinical trials: Paraganglioma/ Phaeochromocytoma
Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
The aim of our study is to compare plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease and possible association with chronic hypoxic stress.
- Conditions
- Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease, Pheochromocytoma, Paraganglioma
- Trial name
- NCT04891081
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- University Medical Centre Ljubljana
Pheochromocytoma, Neuroblastoma
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
- Conditions
- Pheochromocytoma, Neuroblastoma, Paraganglioma, Medullary Thyroid Carcinoma
- Trial name
- NCT01373736
- Testing
- 123I-meta-iodobenzylguanidine
- Where
- Canada
- Sponsor
- Vancouver Coastal Health
Pheochromocytoma, Paraganglioma
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous.
- Conditions
- Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions
- Trial name
- NCT03160274
- Testing
- Genetic screening
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Autonomic Nervous System Disease, Healthy
Blood Sampling for Neurochemical and Genetic Testing
This study involves sampling blood from both normal volunteers and patients with diseases known or suspected to involve body chemicals called catecholamines.
- Conditions
- Autonomic Nervous System Disease, Healthy, Hypertension, Pheochromocytoma
- Trial name
- NCT00001147
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first…
- Conditions
- Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04394858
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging
- Where
- 163 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytoma, Paraganglioma
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Background: Most treatments for malignant pheochromocytomas/paragangliomas (PHEO/PGL) are palliative and multidisciplinary. Chemotherapy using the combination of cyclophosphamide, vincristine, and dacarbazine has been…
- Trial name
- NCT01967576
- Testing
- Axitinib (AG-013736)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)